HemmerBWiendlHRothK, et al. Efficacy and safety of proposed biosimilar natalizumab (PB006) in patients with relapsing-remitting multiple sclerosis. JAMA Neurol2023; 80(3): 298–307.
2.
InojosaHKatherAAkgünK, et al. Challenges and implications of anti-JCV antibody serology variability among different assays in natalizumab treatment: A call for standardization and transparency in clinical practice. Mult Scler J2024; 31: 376–377.
3.
VukusicSHubbenFGavoilleA, et al. Beyond the switch to the biosimilar of natalizumab—What is the impact of changing the JCV test?Mult Scler2025; 31(7): 877–881.
4.
VarleyJBeyroutiRNicholasR, et al. A comparison of JC virus assay performance provided with originator and biosimilar natalizumabMult Scler2025; 31(7): 882–884.
5.
GelissenLMYWijburgMTStrijbisEMM, et al. Accuracy of new John Cunningham virus antibody assay in natalizumab-treated patients with multiple sclerosis. JAMA Neurol2025; 82(5): 523–525.
6.
Bernard-ValnetRKoralnikIJDu PasquierR. Advances in treatment of progressive multifocal leukoencephalopathy. Ann Neurol2021; 90(6): 865–873.
